Development Generally. As of the Effective Date and subject always to Pfizer’s retained rights to the Patents and Licensed Know-How and the limitations and restrictions set forth herein, Licensee shall have full control, responsibility (financial and otherwise) and authority, at Licensee’s cost and expense, over development, registration, importation, manufacture, and Commercialization of the Licensed Products to be sold or supplied by Licensee in the Territory under this Agreement.
Development Generally. As of the Effective Date and subject always to Shionogi's retained rights to the Patents and Licensed Know-How and the limitations and restrictions set forth herein, Licensee shall have full control, responsibility (financial and otherwise) and authority, at Licensee's cost and expense, over development, registration, importation, manufacture, and Commercialization of the Licensed Products to be sold or supplied by Licensee in the Territory under this Agreement.
Development Generally. After the Research Term and subject to Sections 3.6.2, 5.4.1(a) and (b), 5.4.2 and 5.4.3, Novartis will be solely responsible for conducting, at its sole expense, the Development of its Products as it determines appropriate in its sole discretion.
Development Generally. As of the Effective Date and subject always to Xxxxxx’s retained rights to the Patents and Licensed Know-How and the limitations and restrictions set forth herein, Licensee shall have full control, responsibility (financial and otherwise) and authority, at Licensee’s cost and expense, over development, registration, importation, manufacture, and Commercialization of the Licensed Products to be sold or supplied by Licensee in the Territory under this Agreement.
Development Generally. Both Valeant and Meda have the right to undertake development work (whether alone or together) in respect of products that fall within the scope of the Licensed Patents, Licensed Know-How or Licensed Clinical Data, in particular on any new formulations of such products. In the event that a Party intends to undertake development work, prior to commencing such development work, the Party undertaking such development work shall notify the other Party and provide it with details of the proposed development work. ***, the JSC shall meet to agree, in accordance with the terms of Clauses 3.4 and 3.5, to the terms of a development plan in respect of the development work to be undertaken (“Development Plan”). Such development work shall be conducted in accordance with the Development Plan.
Development Generally. The Parties’ respective responsibilities for the research and Development of the Product are set forth in this Article 3 and in the Development Plan. Each Party agrees that in performing its obligations under this Agreement (a) it shall comply with all applicable current international regulatory standards, including Good Laboratory Practice, Good Manufacturing Practice and Good Clinical Practice and other rules, regulations and requirements and (b) it will not employ or use any person that has been debarred under Section 306(a) or 306(b) of the US Federal Food, Drug and Cosmetic Act (or similar sanctions in other countries).
Development Generally. Commencing upon the Effective Date and subject to Section 4 and other terms of this Agreement, as between Durect and Alpharma, Alpharma shall be responsible, at its sole Cost, for development of and procuring Regulatory Approval for the Product in the Territory (all such activities the “Development Program”).
Development Generally. Subject to the terms and conditions of this 2013 Construction Coordinating Agreement, including the scheduling of Work in accordance with the Master Project Schedule, the limitations set forth in the Budget and the general scope of services set forth in the CM Agreement, the Parties shall endeavor in good faith to design, construct, operate and use the Project, as contemplated in this 2013 Construction Coordinating Agreement.
Development Generally. Upon and following the Completion of a Research Program and Adaptimmune’s exercise of its Option with respect to a Development Candidate, Adaptimmune shall (a) have the sole responsibility for development of such Development Candidate from filing of an IND through clinical studies into a pharmaceutical Product containing such Development Candidate for use in the Field, and (b) use Commercially Reasonable Efforts to develop such Product in the Field.
Development Generally. As soon as reasonably practicable following the Effective Date, the parties will jointly agree in writing on a detailed plan defining and describing each party’s responsibilities in connection with the Development Program (the “Development Program Plan”). The parties will jointly develop the Platform or Platforms in accordance with the Development Program Plan as mutually agreed to by the parties. The current proposed architecture for the Platform(s) is listed in Exhibit A and the development activities and milestones to be undertaken generally under the Development Program are listed in Exhibit B.
